Kueh Y K, Tan Y O, Suri R, Oon C J
Ann Acad Med Singap. 1981 Jul;10(3):353-63.
The advances in chemotherapy, understanding of leukaemia cell biology and supportive care for acute leukaemia patients offer substantial prospect for cure in the future. Intensive treatment of acute leukaemia requires the resources of specialised unites for support of bone marrow failure. Where possible, patients should be referred to such units for diagnostic classification and intensive remission induction therapy. The understanding of leukaemia cell biology and the detection of colony stimulating activity in normal granulocytes and marrow has helped in predicting early relapses in leukaemia patients. Allogeneic sibling bone marrow transplantation for patients in remission offers a 70% chance of 3 years survival and disease-free state compared to 10% survival for the non-grafted patients treated on maintenance chemotherapy alone. Current evidence suggests that such transplanted patients do not require long term chemotherapy or anti-G.V.H. treated now that the problem of graft-versus-host disease in transplant recipients appears to be overcome by the use of Cyclosporin A.
化疗的进展、对白血病细胞生物学的认识以及对急性白血病患者的支持性护理为未来治愈该病带来了巨大希望。急性白血病的强化治疗需要专门单位的资源来支持骨髓衰竭。只要有可能，患者应被转诊至此类单位进行诊断分类和强化缓解诱导治疗。对白血病细胞生物学的了解以及对正常粒细胞和骨髓中集落刺激活性的检测有助于预测白血病患者的早期复发。与仅接受维持化疗的未移植患者10%的生存率相比，缓解期患者接受同胞异基因骨髓移植有70%的机会实现3年生存且无病状态。目前的证据表明，由于使用环孢素A似乎已克服了移植受者的移植物抗宿主病问题，此类移植患者不需要长期化疗或抗移植物抗宿主病治疗。
